Amendments to the Claims:

Listing of Claims:

1. (Original) A compound of formula 1

$$\begin{array}{c|c}
R_1 \\
R_2 \\
R_3 \\
R_4
\end{array}$$

wherein

represents hydrogen;

 R_1 represents hydrogen and R_2 represents NR_5R_6 , or R_1 represents NR_5R_6 and R_2 represents hydrogen;

R₃ represents lower alkyl, fluoroalkyl, hydroxyalkyl or carbamoyl;

R4 represents hydrogen, lower alkyl or halogen; and

 R_5 and R_6 represent, independently of each other, hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkyl, lower acyloxy-lower alkyl, carboxy-lower alkyl, lower alkyl, lower alkyl, lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di(lower alkyl)amino-lower alkyl, N-lower alkylpiperidinyl, N-lower alkylpyrrolidinyl, or lower acyl, or R_5R_6 together represent alkylene with four, five or six carbon atoms, oxa-lower alkylene with one oxygen and three or four carbon atoms, or aza-lower alkylene with one nitrogen and three or four carbon atoms wherein the nitrogen atom is unsubstituted or substituted by lower alkyl, hydroxy-lower alkyl, and wherein lower alkylene in each case may be partially or totally unsaturated and/or the carbon atoms of lower alkylene may be substituted by lower alkyl, hydroxy or lower alkoxy; and a N-oxide or a pharmaceutically acceptable salt of such a compound.

2. (Original) A compound of formula 1 according to claim 1 wherein R_{1} represents hydrogen and R_{2} represents NR $_{6}R_{6}$, or R_{1} represents NR $_{5}R_{6}$ and R_{2}

R₃ represents lower alkyl, fluoroalkyl, hydroxyalkyl or carbamoyl;

R4 represents lower alkyl; and

 $R_{\rm S}$ and $R_{\rm G}$ represent, independently of each other, hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkyl, lower alkyl, lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di(lower alkyl)amino-lower alkyl, N-lower alkylpiperidinyl, N-lower alkylpyrrolidinyl, or lower acyl, or $R_{\rm S}R_{\rm G}$ together represent alkylene with four, five or six carbon atoms, oxa-lower alkylene with one oxygen and three or four carbon atoms, or aza-lower alkylene with one nitrogen and three or four carbon atoms wherein the nitrogen atom is unsubstituted or substituted by lower alkyl, hydroxy-lower alkyl or lower alkoxy-lower alkyl, and wherein lower alkylene in each case may be partially or totally unsaturated and/or the carbon atoms of lower alkylene may be substituted by lower alkyl, hydroxy or lower alkoxy;

and a N-oxide or a pharmaceutically acceptable salt of such a compound.

3. (Original) A compound of formula 1 according to claim 1 wherein R_1 represents hydrogen and R_2 represents NR_5R_6 , or R_1 represents NR_5R_6 and R_2 represents hydrogen;

R₃ represents trifluoromethyl;

R₄ represents methyl; and

R₅ and R₆ represent, independently of each other, hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkyl, lower alkyl, lower alkyl, lower alkyl, carboxy-lower alkyl, lower alkyl, lower alkyl, di(lower alkyl)amino-lower alkyl, mino-lower alkyl, N-lower alkylpipendinyl, N-lower alkylpyrrolidinyl, or acetyl, or R₅R₆ together represent akylene with four, five or six carbon atoms, oxa-lower alkylene with one oxygen and three or four carbon atoms, or aza-lower alkylene with one nitrogen and three or four carbon atoms wherein the nitrogen atom is unsubstituted or substituted by lower alkyl, hydroxy-lower alkyl or lower alkoxy-lower alkyl, and wherein lower alkylene in each case may be partially or totally unsaturated and/or the carbon atoms of lower alkylene may be substituted by lower alkyl, hydroxy or lower alkoxy;

and a N-oxide or a pharmaceutically acceptable salt of such a compound.

4. (Original) A compound of formula 1 according to claim 1 wherein R_1 represents hydrogen and R_2 represents NR₅R₆, or R_1 represents NR₅R₆ and R_2 represents hydrogen;

R₃ represents trifluoromethyl:

R₄ represents methyl; and

R₅ and R₆ represent, independently of each other, hydrogen, lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di(lower alkyl)amino-lower alkyl, N-lower alkylpiperidinyl, or lower acyl, or R₅R₆ together represent alkylene with four or five carbon atoms, oxa-lower alkylene with one oxygen and three or four carbon atoms, or azalower alkylene with one nitrogen and three or four carbon atoms wherein the nitrogen atom is unsubstituted or substituted by lower alkyl, hydroxy-lower alkyl or lower alkoxy-lower alkyl, and wherein lower alkylene in each case may be partially or totally unsaturated and/or the carbon atoms of lower alkylene may be substituted by lower alkyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.

5. (Original) A compound of formula 1 according to claim 1 wherein R₁ represents hydrogen and R₂ represents NR₅R₆, or R₁ represents NR₅R₆ and R₂ represents hydrogen;

R₃ represents trifluoromethyl;

R4 represents methyl; and

 $R_{\rm S}$ and $R_{\rm B}$ represent, independently of each other, hydrogen, lower alkyl, di(lower alkyl)amino-lower alkyl, N-lower alkylpiperidinyl, or lower acetyl, or $R_{\rm S}R_{\rm B}$ together represent alkylene with four or five carbon atoms, oxa-lower alkylene with one oxygen and four carbon atoms, or aza-lower alkylene with one nitrogen and three or four carbon atoms wherein the nitrogen atom is unsubstituted or substituted by lower alkyl, and wherein aza-lower alkylene may be unsaturated and/or the carbon atoms of aza-lower alkylene may be substituted by lower alkyl;

and a N-oxide or a pharmaceutically acceptable salt of such a compound.

6. (Original) A compound of formula 1 according to claim 1 wherein R₁ represents hydrogen and R₂ represents NR₅R₆, or R₁ represents NR₅R₆ and R₂ represents hydrogen;

R₃ represents trifluoromethyl;

R4 represents methyl; and

R₅ and R₆ represent, independently of each other, hydrogen, methyl, ethyl, 2-dimethylaminoethyl, 4-methyl-1-piperidinyl, or acetyl, or NR₅R₆ together represent pyrrolidino, piperidino, morpholino, N-methylpiperazino, 1H-imidazolyl, 1H-2-methylimidazolyl or 1H-2,4-dimethylimidazolyl; and a N-oxide or a pharmaceutically acceptable salt of such a compound.

7. (Original) A process for the synthesis of a compound of the formula 1

$$\begin{array}{c|c}
R_1 \\
R_2 \\
R_3 \\
\end{array}$$

or an N-oxide or a salt thereof, wherein the symbols R_1 , R_2 , R_3 and R_4 are as defined in claim 1, characterized in that a compound of formula 2

wherein R_1 , R_2 and R_3 are as defined for a compound of formula 1, or a derivative thereof wherein the carboxy group —COOH is in activated form, is reacted with an amine of the formula 3

32700A-US-PCT

wherein R₄ is as defined for a compound of the formula 1, optionally in the presence of a dehydrating agent and an inert base and/or a suitable catalyst, and optionally in the presence of an inert solvent;

where the above starting compounds of formula 2 and 3 may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible;

any protecting groups in a protected derivative of a compound of the formula 1 are removed; and, if so desired, an obtainable compound of formula 1 is converted into another compound of formula 1 or a N-oxide thereof, a free compound of formula 1 is converted into a salt, an obtainable salt of a compound of formula 1 is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula 1 is separated into the individual isomers.

- 8. (Original) A pharmaceutical composition comprising as an active ingredient a compound of formula 1 according to claim 1 or a N-oxide or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
- 9.-10. (Cancelled)
- 11. (Currently Amended) A method for the treatment of a disease which responds to an inhibition of protein kinase activity, which comprises administering a compound of formula 1 according to claim 1 or a N-oxide or a pharmaceutically acceptable salt thereof, wherein said disease is a leukemia which responds to an inhibition of the Raf and/or Abi tyrosine kinase activity.
- 12.-13. (Cancelled)